抗体药物偶联物治疗肺癌不良反应多学科管理中国专家共识(2025版)
该共识由中国老年保健协会胸部肿瘤精准治疗分会牵头,组织消化科、皮肤科、呼吸科、眼科及肿瘤科等多学科专家制定,针对肺癌领域ADC药物相关不良反应提出21条推荐意见。共识涵盖ADC使用前安全评估、治疗期间不良反应的全面监测管理、患者教育及特殊人群用药指导,旨在为临床医师提供切实可行的ADC应用参考准则。
要点
- ADC常见不良反应涉及消化、血液、肝胆、肺部、皮肤、眼部、外周感觉神经及肌肉骨骼系统。
- 晚期肺癌患者常合并慢阻肺、肺部炎症等共患病,ADC不良反应全程管理更具挑战。
- 共识提出21条推荐意见,贯穿ADC使用前评估、治疗期间监测管理及特殊人群用药指导。
核心结论
- 共识旨在为临床医师提供切实可行的ADC应用参考准则,确保肺癌患者治疗获益最大化。
研究设计与样本
- 由中国老年保健协会胸部肿瘤精准治疗分会专业委员会牵头,组织国内消化科、皮肤科、呼吸科、眼科及肿瘤科等多学科专家讨论并联合制定。
主要发现
- 根据已披露的肺癌领域ADC安全性数据,常见药物不良反应主要涉及消化系统、血液系统、肝胆系统、肺部、皮肤、眼部、外周感觉神经系统及肌肉骨骼系统。
- 晚期肺癌患者常合并慢性阻塞性肺疾病、肺部炎症等多种共患病,致使ADC相关不良反应的全程化管理更具挑战。
关键数值与推荐
- 共识共提出21条推荐意见,贯穿ADC使用前安全评估、ADC治疗期间相关不良反应的全面监测管理、患者教育以及特殊人群的用药指导。
临床怎么用
- 临床医师可参照共识推荐意见,在ADC使用前进行安全评估,治疗期间全面监测管理相关不良反应,并开展患者教育及特殊人群用药指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody-drug conjugates (ADCs) are covalently conjugated molecules composed of a monoclonal antibody, a payload, and a linker. They represent an innovative therapeutic approach that combines the precise targeting capability of target therapies with the cytotoxic effects of chemotherapeutic agents. Given the unique molecular structure of ADCs, drug-related adverse reactions have drawn a considerable attention. Based on the safety data of ADCs currently available in the field of lung cancer, the common adverse drug reactions primarily involve the digestive system, hematologic system, hepatobiliary system, pulmonary system, skin, eyes, sensory nervous system, and musculoskeletal system. Unlike other cancer types, lung cancer is characterized by complex disease subtypes and molecular pathological mechanisms, as well as diverse treatment modalities. Moreover, patients with advanced lung cancer often have comorbidities such as chronic obstructive pulmonary disease and pulmonary inflammation, making the comprehensive management of ADC-related adverse reactions even more challenging. To address this, the Precision Treatment Branch of Thoracic Oncology, Chinese Geriatric Health Association, has taken the lead in organizing a multidisciplinary panel of domestic experts in gastroenterology, dermatology, respiratory medicine, ophthalmology and oncology, to discuss and jointly formulate the "Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of Lung Cancer (2025 edition)". A total of 21 recommendations are proposed in this consensus, covering pre-ADC safety assessments, comprehensive monitoring and management of relevant adverse reactions during ADC treatment, patient education, and medication guidance for special populations. The consensus aims is to provide clinicians with practical guidelines for the application of ADC, thereby maximizing therapeutic benefits for patients with lung cancer. 抗体药物偶联物(ADC)由单克隆抗体、有效载荷和连接子3部分共价偶联组成,是将靶向药物的精准定位与化疗药物的细胞毒性杀伤作用相结合的创新疗法。鉴于ADC独特的分子结构,其药物相关的不良反应一直备受关注。根据已披露的肺癌领域ADC安全性数据,目前常见的药物不良反应主要涉及消化系统、血液系统、肝胆系统、肺部、皮肤、眼部、外周感觉神经系统及肌肉骨骼系统等。与其他癌种不同的是,肺癌不仅疾病亚型及分子病理学机制复杂,治疗模式多样,而且晚期肺癌患者常合并慢性阻塞性肺疾病、肺部炎症等多种共患病,致使ADC相关不良反应的全程化管理更具挑战。为此,由中国老年保健协会胸部肿瘤精准治疗分会专业委员会牵头,组织国内消化科、皮肤科、呼吸科、眼科及肿瘤科等多学科专家讨论并联合制定了《抗体药物偶联物治疗肺癌不良反应多学科管理专家共识(2025版)》,共提出21条推荐意见,贯穿ADC使用前安全评估、ADC治疗期间发生相关不良反应的全面监测管理、ADC治疗的患者教育以及特殊人群的用药指导,旨在为临床医师提供切实可行的ADC应用参考准则,确保肺癌患者治疗获益最大化。.
引用
- [Consensus of Chinese experts on the multidisciplinary management of adverse reactions to antibody-drug conjugates in the treatment of lung cancer (2025 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42331546. doi:10.3760/cma.j.cn112152-20251113-00569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。